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OBJECTIVE—Cyclin-dependent kinase 5 (CDK5) regulatory
subunit-associated protein 1-like 1 has recently been linked to
type 2 diabetes by genome-wide association studies. While CDK5
and its regulatory protein p35 are both expressed and display
enzymatic activity in pancreatic b-cells, their precise role in the
b-cell remains unknown. Because type 2 diabetes is character-
ized by a deﬁcit in b-cell mass and increased b-cell apoptosis, we
investigated the role of CDK5 in b-cell survival.
RESEARCH DESIGN AND METHODS—We used INS 832/13
cells, rat islets isolated from wild-type or human islet amyloid
polypeptide (h-IAPP) transgenic rats, and pancreatic tissue from
rats and humans with and without type 2 diabetes and in-
vestigated the effect of CDK5/p35 inhibition (by small interfering
RNA or by chemical inhibition) as well as CDK5/p35 over-
expression on b-cell vulnerability to apoptosis.
RESULTS—CDK5 inhibition led to increased b-cell apoptosis.
To identify the mechanisms involved, we examined the phosphor-
ylation state of focal adhesion kinase (Fak)
Ser732, a known target
of CDK5. Following CDK5 inhibition, the phosphorylation of
Fak
Ser732 decreased with resulting attenuation of phosphatidyl-
inositol 3-kinase (PI3K)/Akt survival pathway. Conversely,
CDK5 overexpression increased Fak
Ser732 phosphorylation and
protected b-cells against apoptosis induced by the inhibition of
the b-1 integrin signaling pathway. Also, Fak
Ser732 phosphoryla-
tion was less abundant in b-cells in both h-IAPP transgenic rats
and humans with type 2 diabetes.
CONCLUSIONS—This study shows that by regulating Fak
phosphorylation and subsequently PI3K/Akt survival pathway,
CDK5 plays a previously unrecognized role in promoting b-cell
survival. Diabetes 60:1186–1197, 2011
G
enome-wide association studies have identiﬁed
a variant of the cyclin-dependent kinase 5
(CDK5) regulatory subunit-associated protein
1-like 1 (CDKAL1) to be associated with type 2
diabetes (1–5). CDK5 is a serine/threonine kinase ubiqui-
tously expressed in mammalian tissues, with a best char-
acterized functional role in the central nervous system (6).
CDK5 has no enzyme activity as a monomer, and its acti-
vation requires association with a regulatory protein, p35
or p39, abundantly expressed in the brain. CDK5 and its
regulatory proteins, p35 and p39, are also expressed in
pancreatic b-cells where complexes CDK5/p35 and CDK5/
p39 display enzymatic activity (7,8). Type 2 diabetes is
characterized by a deﬁcit in b-cell mass with increased
b-cell apoptosis as well as a deﬁcit in b-cell function (9).
To date, while a few studies have investigated the potential
role of CDK5 in b-cell function (8,10–13), its role in b-cell
survival has not been addressed.
Neurons in Alzheimer’s disease and b-cells in type 2
diabetes are characterized by endoplasmic reticulum (ER)
stress-induced apoptosis associated with formation of
misfolded toxic oligomers of locally expressed amyloido-
genic proteins (Alzheimer’s b-protein [AbP] in brain and
islet amyloid polypeptide [IAPP] in b-cells) (14,15). There
is an unexplained shared predisposition to type 2 diabetes
and Alzheimer’s disease while variance in CDK5 and its
binding partners is linked to risk for Alzheimer’s disease in
a high-risk population (16,17). It has been proposed that
AbP misfolding, through aberrant proteolytic cleavage of
p35 to generate the truncated p25 fragment, induces hyper-
activation and mislocalization of CDK5 in neurons that in
turn leads to neuronal dysfunction and apoptosis (18).
In the present studies, we ﬁrst tested the hypothesis that
the CDK5 complex acts as an intermediary between IAPP
misfolding and b-cell apoptosis. In contrast to AbP, sufﬁ-
cient expression of human-IAPP (h-IAPP) to induce apo-
ptosis did not induce hyperactivation of the CDK5/p35
complex. In contrast, we established that the CDK5/p35
complex is protective in b-cells. Further investigation
revealed that in b-cells, the prosurvival mechanism medi-
ated by the CDK5/p35 complex is accomplished by acti-
vation of focal adhesion kinase (Fak) and Akt signaling
pathways. We conclude that genome-wide association
studies linkage of CDKAL1 to type 2 diabetes may reﬂect
the prosurvival properties of the CDK5 complex in b-cells.
RESEARCH DESIGN AND METHODS
Cell culture. Rat insulinoma cell line INS 832/13 (19) was kindly provided by
Dr. C. Newgard (Duke University Medical Center, Durham, NC). Cells were
grown in RPMI-1640 medium supplemented with 10 mmol/L HEPES, 1 mmol/L
sodium pyruvate, 100 IU/mL penicillin, 100 µg/mL streptomycin (Invitrogen,
Carlsbad, CA), 10% heat-inactivated FBS (Gemini, West Sacramento, CA), and
50 mmol/L b-mercaptoethanol (Sigma, St. Louis, MO) at 37°C in a humidiﬁed
5% CO2 atmosphere.
Transduction experiments. INS 832/13 cells were plated in 6-well plates at
1.0 3 10
6 cells/well and cultured overnight. Cells were transduced with rodent-
IAPP (r-IAPP) or h-IAPP adenoviruses (400 moi [multiplicity of infection], 48 h)
in complete RPMI-1640 medium and lysed in NP40 buffer (50 mmol/L Tris-HCl,
pH 7.4, 250 mmol/L NaCl, 1 mmol/L EDTA, 0.5% NP40, 1 mmol/L dithiothreitol
and protease inhibitors [Sigma]).
Islet isolation. Wild-type (WT) and h-IAPP transgenic (HIP) rats were bred
and housed at the animal housing facility of the University of California, Los
Angeles (UCLA). The UCLA Institutional Animal Care and Use Committee
approved all surgical and experimental procedures. The generation of HIP rats
has been previously described (20). Islets from WT and HIP rats
(Supplementary Table 1) were isolated as described (21).
Roscovitine treatment. Islets from 2-month-old WT rats (n =7 )w e r ec u l -
tured 24 h in RPMI-1640 medium supplemented with 100 IU/mL penicillin,
100 mg/mL streptomycin, and 10% heat-inactivated FBS at 37°C in a humidiﬁed
5% CO2 atmosphere. Islets were treated 48 h with 10 mmol/L roscovitine
(Calbiochem, La Jolla, CA) or DMSO (vehicle, Sigma).
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Small interfering RNA. CDK5 (ACCTACGGAACTGTGTTCAAGGCCA) and
Fak (CAGTACTTACTATAAAGCTTCCAAA) small interfering RNAs (siRNAs)
were purchased from Invitrogen. p35 (AAGAGGATCGTGGCGGTGTCA) and
scramble (AF488) siRNAs were purchased from Qiagen (Valencia, CA). INS 832/
13 were seeded in 12-well plates (0.25 3 10
6 cells/well), cultured overnight, and
transfected with 50 nmol/L siRNA using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. After 24 h, cells were transduced
with r-IAPP or h-IAPP adenoviruses and cultured for an additional 24 h.
Plasmids. CDK5-green ﬂuorescent protein (GFP) (#1346) and p35 (#1347)
plasmids were obtained from the plasmid repository Addgene. INS 832/13 were
seeded in 12-well plates (0.5 3 10
6 cells/well), cultured overnight, and trans-
fected for 24 and 48 h with 0.2 mg or 0.4 mg of CDK5 and/or p35 or pCMV-GFP
(as control) plasmids according to the manufacturer’s instructions.
pBabe/Fak stable lines. INS 832/13 were transduced with pBabe and Fak
retroviruses in complete RPMI-1640 medium supplemented with 4 mg/mL
protamine sulfate (Sigma) and selected 72-h post-transfection with 0.5 mg/mL
puromycin.
Western blotting. Proteins were separated on a 4–12% Bis-Tris NuPAGE gel
and blotted onto a nitrocellulose membrane (Whatman, Germany). Mem-
branes were probed overnight at 4°C with CDK5 (DC17), P-Fak
Ser732, insulin
receptor substrate (IRS) 2 (Millipore/Upstate, St. Louis, MO), C/EBP homol-
ogous protein (CHOP) (Sc-575, lot #L057; Santa Cruz Biotechnology, Santa
Cruz, CA), p35 (#2680), p35/p25 (#2673), P-Bad
Ser136, Bad, P-Akt
Ser473, Akt,
P-ERK1/2, ERK1/2, Fak, cleaved caspase-3, PARP, b-actin, and glyceraldehyde-
3-phosphate dehydrogenase (Cell Signaling Technology, Beverly, MA) antibodies,
followed by incubation with horseradish peroxidase-conjugated secondary
antibodies (Zymed Laboratories, South San Francisco, CA). Proteins were
visualized by enhanced chemiluminescence (Millipore), and protein levels
were quantiﬁed using the Labworks software (UVP, Upland, CA).
b-1 integrin blockade. INS 832/13 cells were trypsinized and preincubated in
suspension for 1 h at 37°C with or without 20 mg/mL b-1 integrin blocking
antibody (CD29, Ha2/5, hamster antirat) or hamster IgM as control (G235–1)
(BD Bioscience, San Jose, CA) in RPMI-1640 medium supplemented with 10
mmol/L HEPES, 1 mmol/L sodium pyruvate, 100 IU/mL penicillin, 100 µg/mL
streptomycin, 1% heat-inactivated FBS, and 50 mmol/L b-mercaptoethanol.
Cells were replated in 8-well chamber slides coated with collagene I (BD
Bioscience) at 0.15 3 10
6 cells/well and cultured for 24 h in the presence or
absence of antibodies.
Immunoﬂuorescence staining cells and tissue. INS832/13 cells were plated
in 4-well chamber permanox slides (Permanox Nunc, Rochester, NY) or 8-well
chamber slides coated with collagen. After treatment, cells were ﬁxed 30 min at
room temperature in 4% paraformaldehyde.
Rat tissue. Pancreata were obtained from WT, prediabetic HIP and diabetic
HIP rats (Supplementary Table 1). Frozen sections were prepared from 4%
paraformaldehyde-ﬁxed tissue embedded in optimal cutting temperature
compound.
Human tissue. Cases studied are summarized in Supplementary Table 2 and
previously described (14). Surgically removed human pancreas specimens
were obtained in accordance with UCLA Institutional Review Board approval.
Pancreata from type 2 diabetic versus nondiabetic control subjects were ﬁxed
overnight in 4% formaldehyde and frozen in optimal cutting temperature
compound. Cells and pancreatic sections were permeabilized in 0.4% Triton
X-100/TBS and stained as previously described (21).
Propidium iodide staining. INS 832/13 cells were plated as described above.
Aliquots of 30 islets isolated from WT rats were cultured in 8-well chamber
slides. After treatment, cells or islets were incubated 30 min at 37°C with
50 mg/mL propidium iodide (PI) (Molecular Probes, Eugene, OR) and ﬁxed
30 min at room temperature in 4% paraformaldehyde. Cells (3,000–6,000 per
condition) and islets (30 per condition) were imaged using a Leica DM6000
microscope (Leica Microsystems, Wetzlar, Germany). For rat islets, PI positive
area was quantiﬁed using Image-Pro Plus software (Media Cybernetics, Silver
Spring, MD). In CDK5/p35 overexpression experiments, for each condition, all
cells, transfected and nontransfected were counted without distinction and
included in the analysis.
Statistical analysis. Data are presented as means 6 SEM. Statistical analyses
were carried out by Student t test or ANOVA followed by Duncan post hoc test
for multiple comparisons using Statistica (Statsoft, Tulsa, OK). A P value of
,0.05 was taken as evidence of statistical signiﬁcance.
RESULTS
Speciﬁc inhibition of the complex CDK5/p35 by
siRNA does not prevent h-IAPP–induced apoptosis.
Apoptosis induced by h-IAPP was assessed in INS 832/13
cells transduced with adenoviruses expressing h-IAPP or
the non-amyloidogenic, non-toxic r-IAPP, as control for a
comparable burden of protein expression. As described
previously, high expression rates of h-IAPP increased
caspase-3 cleavage in comparison with r-IAPP–transduced
cells (Fig. 1A). To determine whether inhibition of CDK5
would suppress h-IAPP–induced b-cell apoptosis, we
transfected INS 832/13 cells with CDK5 siRNA or scramble
and transduced these cells with h-IAPP or r-IAPP adeno-
viruses. CDK5 siRNA decreased CDK5 expression without
interfering with p35 expression, but did not decrease
h-IAPP–induced apoptosis as determined by cleaved
caspase-3 Western blot (Fig. 1B).
Because CDK5 is usually activated by complex formation
with p35, we probed the role of the CDK5/p35 complex in
h-IAPP–induced apoptosis by the alternative approach of
knocking down p35. Despite successful knockdown of p35,
cells were not protected against h-IAPP–induced apoptosis
(Fig. 1C). Inhibition of the CDK5/p35 complex by either
CDK5 or p35 knockdown failed to prevent h-IAPP–induced
apoptosis. In contrast, as shown in Fig. 1B and C, inhibition
of CDK5/p35 complex in b-cells potentiated h-IAPP toxicity
and was sufﬁcient by itself to induce apoptosis in control
cells (P , 0.05).
We also investigated whether disturbed intracellular
Ca
2+ homeostasis and h-IAPP would induce the cleavage
of p35 to generate the p25 truncated fragment and sub-
sequently promote CDK5 hyperactivation in b-cells. Treat-
ment of INS 832/13 cells either with the ER stress inducer
thapsigargin or the Ca
2+ ionophore A23187 induced p35
cleavage (Supplementary Fig. 1A). However, neither p25/
p35 ratio, p35, nor CDK5 expression was affected by h-IAPP
in INS 832/13 cells (Supplementary Fig. 1B)o ri nH I Pr a t
islets (Supplementary Fig. 1C) despite the presence of ER
stress and apoptosis illustrated by increased CHOP expres-
sion and caspase-3 cleavage, respectively. In addition, cy-
toplasmic and nuclear distribution of CDK5 and p35 was not
affected in cells expressing h-IAPP (Supplementary Fig. 2).
Collectively, the absence of effect of CDK5 or p35
knockdown on h-IAPP–induced apoptosis and the absence
of effect of high expression rates of h-IAPP sufﬁcient to
induce apoptosis on CDK5 or p35 levels in INS 832/13 cells
and primary b-cells, lead to rejection of the stated hy-
pothesis that h-IAPP–induced b-cell apoptosis is mediated
by CDK5 hyperactivation.
Speciﬁc inhibition of the complex CDK5/p35 by siRNA
increases INS 832/13 cell vulnerability to apoptosis.
In the data presented in Fig. 1, the loss of CDK5 activity
seemed to be sufﬁcient to promote b-cell apoptosis. To
conﬁrm and extend this observation, cells were trans-
fected with CDK5 or p35 siRNAs alone, avoiding any bias
introduced by the adenoviral transduction. CDK5 siRNA
led to a 60% decrease in CDK5 expression (P , 0.01)
(Fig. 2A). Supporting the results obtained in the previous
experiment, CDK5 knockdown led to a threefold increase in
caspase-3 cleavage (P , 0.01) (Fig. 2A). A similar increase
in apoptosis was also observed in cells transfected with p35
siRNA, in which a 50% decrease in p35 levels led to a four-
fold increase in cleaved caspase-3 (P , 0.01) (Fig. 2B).
Apoptosis induction following CDK5 or p35 knockdown
was also conﬁrmed by PI staining (P , 0.01) (Fig. 2C).
Therefore, these results suggest a role of CDK5/p35 ac-
tivity in b-cell survival.
Loss of CDK5 activity results in the attenuation of
the Fak/Akt survival pathway. To further investigate the
role of CDK5 in b-cell survival and identify downstream
signaling pathways, we examined the effect of CDK5
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Ser732, identiﬁed as
CDK5 target in neurons (22). As shown in Fig. 3A,C D K 5
k n o c k d o w nl e dt oa4 0 %d e c r e a s ei nF a k
Ser732 phosphoryla-
tion (P , 0.05). This effect also correlated with a decrease in
P-Fak
Tyr397 (P , 0.05), suggesting a decrease in Fak kinase
activity (Supplementary Fig. 3A). Fak is known to regulate
prosurvival pathways including ERK1/2 and phosphatidy-
linositol 3-kinase (PI3K)/Akt pathways (23), also involved
in b-cell survival (24). In cells transfected with CDK5
siRNA, the level of P-ERK1/2 remained unchanged compared
with control cells (Fig. 3B). However, with regard to PI3K/
Akt pathway, we found that CDK5 inhibition and sub-
sequently Fak inhibition led to a decrease in P-Akt
Ser473
(70%, P , 0.01). P-Akt
Ser473 promotes cell survival by
phosphorylating the transcription factor cAMP-responsive
element-binding protein (CREB). pCREB is known to play
ar o l ei nr e g u l a t i o no ft h eIRS2 gene expression that pro-
motes b-cell survival. P-Akt
Ser473 also increases phos-
phorylation of Bad
Ser136, thereby inhibiting its proapoptotic
activity. CDK5 knockdown led to a decrease in IRS2 protein
FIG. 1. Speciﬁc inhibition of the complex CDK5/p35 by siRNA does not prevent h-IAPP–induced apoptosis. A: INS 832/13 cells were transduced at
400 moi for 48 h with r-IAPP or h-IAPP adenoviruses. IAPP expression and cleaved caspase-3 level (Cl. casp-3) to assess apoptosis were examined
by Western blot. IAPP image was obtained by grouping different parts of the same gel. B and C: INS 832/13 cells were transfected for 48 h with
scramble (Sc), CDK5 (B), or p35 (C) siRNAs (50 nmol/L) and transduced with r-IAPP or h-IAPP (400 moi) for the last 24 h of culture. Protein
levels of CDK5, p35, and cleaved caspase-3 were analyzed by Western blot (left panels). b-Actin was used as loading control. The right panels
represent the quantiﬁcation of cleaved caspase-3 levels (n = 4). *P < 0.05, signiﬁcant differences. RU, relative units.
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Ser136 levels that correlated with an increase
in apoptosis, therefore supporting an attenuation of Akt
signaling pathway (P , 0.01) (Fig. 3C).
Roscovitine treatment decreases Fak/Akt survival
pathway and induces apoptosis in rat islets. To test
whether CDK5 also plays an important role in the sur-
vival of primary b-cells, we investigated the effect of
CDK5 inhibition in rat islets treated with roscovitine,
a chemical inhibitor of CDK5. Roscovitine treatment did
not affect the level of ERK1/2 phosphorylation in rat
islets but led to a decrease in P-FakSer732,P - A k t
Ser473,
IRS2, and P-Bad
Ser136 levels (P , 0.001) (Fig. 4A). This
attenuation in Fak/Akt pathway was accompanied by a
1.6-fold increase in cleaved caspase-3 (P , 0.01), conﬁrmed
by PI staining (P , 0.05) (Fig. 4B and C). A decrease in
P-Fak
Tyr397 was also observed in rat islets following
roscovitine treatment, suggesting a decrease in Fak kinase
activity (P , 0.01) (Supplementary Fig. 3B).
In agreement with the effect of CDK5 knockdown in INS
cells, these data in primary cells indicate that decreased
CDK5 availability leads to b-cell apoptosis. We then
determined whether Fak was the downstream effector
responsible for CDK5 prosurvival activity.
Downstream of CDK5, Fak is directly involved in
b-cell survival. To investigate the link between Fak and
b-cell survival, we ﬁrst examined the consequences of Fak
knockdown on INS 832/13 cell apoptosis. In common with
CDK5 knockdown, we found that the depletion of Fak in-
creased b-cell vulnerability to apoptosis (P , 0.05) (Fig. 5A).
We then examined whether Fak protects b-cells against
apoptosis induced by CDK5 inhibition by overexpressing
Fak (or pBabe as a control) in INS 832/13 that were
treated (or not) with roscovitine. Under basal conditions,
Fak overexpression led to a twofold increase in P-Fak
Ser732
(P , 0.001) (Fig. 5B). The same trend was observed for
P-Akt (Fig. 5B). As expected, roscovitine treatment of con-
trol cells led to a decrease in P-Fak
Ser732 that correlated with
a decreased P-Akt (Fig. 5B) and an increase in apoptosis
(Fig. 5C and D). Although roscovitine also decreased
Fak
Ser732 phosphorylation in Fak-overexpressing cells,
Fak phosphorylation was maintained at higher levels
than in control cells (P , 0.001) (Fig. 5B). Higher levels
FIG. 2. Speciﬁc inhibition of the complex CDK5/p35 by siRNA increases INS 832/13 cell vulnerability to apoptosis. INS 832/13 cells were trans-
fected for 48 h with scramble (Sc), CDK5 or p35 siRNAs (50 nmol/L). A and B: Protein levels of CDK5, p35, and cleaved caspase-3 were analyzed by
Western blot (left panels). b-Actin was used as loading control. The right panels represent the quantiﬁcation of CDK5, p35, and cleaved caspase-3
expressions. C: Cell death was assessed by PI staining (n =4 ) .* * P < 0.01, signiﬁcant differences. RU, relative units. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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following roscovitine treatment (P , 0.05) (Fig. 5B) with
decreased apoptosis assessed both by staining for cleaved
caspase-3 (P , 0.01) (Fig. 5C) and PI staining (P , 0.05)
(Fig. 5D).
Together, these data suggest that the increase in b-cell
apoptosis consistently noted following inhibition of CDK5
expression is at least in part mediated through a decrease
in Fak phosphorylation and the subsequent attenuation of
Akt survival pathway. To further develop the hypothesis of
a prosurvival role of CDK5, we investigated whether CDK5
overexpression would protect b-cells against apoptosis.
CDK5 overexpression protects b-cells against apopto-
sis induced by the inhibition of b-1 integrin signaling
pathway. Fak activation is an early event of the signaling
cascade initiated by integrins to promote cell survival
(25). It is recognized that integrins, especially the b-1
integrin interactions with extracellular matrix, are critical
for b-cell function and survival. We ﬁrst examined the
effect of inhibition of b-1 integrin signaling on CDK5 ac-
tivity. While this inhibition did not affect the protein
levels of CDK5 and p35, it did result in a decrease in
P-Fak
Ser732 and P-Akt, suggesting a decrease in CDK5/p35
complex activity (P , 0.05) (Fig. 6A). These effects were
also associated with a twofold increase in caspase-3
cleavage (P , 0.01) (Fig. 6B). We therefore investigated
the effect of CDK5 or CDK5/p35 overexpression on b-cell
survival following b-1 integrin pathway inhibition. We
ﬁrst conﬁrmed that overexpression of CDK5 or CDK5 in
combination with p35 resulted in an increase in CDK5 and
p35 protein levels (P , 0.001) (Supplementary Fig. 4A)a n d
in Fak
Ser732 phosphorylation levels (P , 0.05) (Supple-
mentary Fig. 4B). We then investigated the effect of this
increased CDK5 activity on b-cell apoptosis induced by b-1
integrin inhibition. As illustrated by PI staining, incubation
of INS 832/13 cells with anti–b-1 integrin blocking antibody
FIG. 3. Loss of CDK5 activity results in the attenuation of the Fak/Akt survival pathway. A–C: INS 832/13 cells were transfected for 48 h with
scramble (Sc) or CDK5 siRNAs (50 nmol/L). Protein levels of CDK5, Fak, Akt, Bad, ERK1/2, cleaved caspase-3, and phosphorylation levels of
Fak
Ser732, Akt
Ser473, ERK1/2, and Bad
Ser136 were analyzed by Western blot (left panels). b-Actin was used as loading control. The right panels
represent the quantiﬁcation of the Western blot (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001, signiﬁcant differences. RU, relative units.
ROLE OF CDK5 IN b-CELL SURVIVAL
1190 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgresulted in a 2.4-fold increase in cell death (P , 0.001)
(Fig. 6C). Both CDK5 and CDK5/p35 overexpression led
to a 50% decrease in b-cell death induced by b-1 integrin
inhibition in comparison with GFP-transfected cells (P ,
0.001) (Fig. 6C).
Altogether these ﬁndings indicate that CDK5 activity, by
promoting Fak
Ser732 phosphorylation, sustains b-cell sur-
vival and is able to protect b-cells against apoptosis induced
by the inhibition of b-1 integrin signaling pathway. Prior
studies have reported that the ERK1/2 signaling pathway is
also implicated in the transduction of cell-matrix signal-
ing in b-cells. We have shown in this study that ERK1/2
activity in b-cells was not dependant on CDK5 activity.
This could therefore explain why cells overexpressing
CDK5 are only partially protected against apoptosis.
To determine if CDK5 activity is also important for b-cell
survival in response to other insults, we used thapsigargin-
induced apoptosis as a model of ER stress and investigated
whether in this context, CDK5 inhibition or activation
would affect b-cell survival. In cells transfected with CDK5
siRNA, a sixfold increase in cleaved caspase-3 was ob-
served in the presence of thapsigargin in comparison with
cells transfected with Sc (P , 0.05) (Supplementary Fig. 5A).
This indicates that the loss of CDK5 activity enhances b-cell
vulnerability to apoptosis induced by thapsigargin. Con-
versely, overexpression of CDK5, with a resulting increase
in P-Fak
Ser732 resulted in partial protection of b-cells from
ER stress-induced apoptosis (P , 0.05) (Supplementary
Fig. 5B), further supporting a prosurvival role of CDK5
activity in b-cells.
FIG. 4. Roscovitine treatment decreases Fak/Akt survival pathway and induces apoptosis in rat islets. A–C: Isolated WT rat islets were cultured in
the absence or presence of roscovitine 10 mmol/L for 48 h. A and B: Protein levels of Fak, IRS2, Akt, Bad, ERK1/2, cleaved caspase-3, and phos-
phorylation levels of Fak
Ser732, Akt
Ser473, ERK 1/2, and Bad
Ser136 were analyzed by Western blot. GAPDH was used as loading control. The graphs
represent the quantiﬁcation of the Western blots. C: Islet apoptosis was assessed by PI staining. The graph represents the quantiﬁcation of the
islet area positive for PI, expressed in % (n = 7). *P < 0.05, **P < 0.01, ***P < 0.001, signiﬁcant differences. RU, relative units. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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role in promoting b-cell survival in response to b-1 integrin
inhibition but also ER stress-induced apoptosis.
Phosphorylation of Fak
Ser732 is decreased in b-cells
in rats with diabetes. Next we investigated whether
ad e ﬁcit in CDK5 activity is associated with the increased
b-cell apoptosis present in type 2 diabetes. We exam-
ined P-Fak
Ser732 as an indirect marker of CDK5 activity
in a rat model of type 2 diabetes, HIP rats that develop
islet pathology comparable to humans with type 2 diabetes
(20). Western blotting for P-Fak
Ser732 was performed on islet
lysates obtained from prediabetic and diabetic HIP rats
and age-matched WT rats (Supplementary Table 1). In
prediabetic HIP rat islets, the level of P-Fak
Ser732 was no
different from that in WT rat islets (Fig. 7A). In agreement
with our previous observation, CDK5 protein levels were
also similar in both genotypes. In contrast, in islets iso-
lated from diabetic HIP rats, there was an approximately
50% decrease in P-Fak
Ser732 in comparison with age-matched
WT rat islets (P , 0.01) (Fig. 7A). There was also a 27%
decrease in the CDK5 protein level in diabetic HIP rat islets
(P , 0.01).
To conﬁrm that the decreased P-Fak
Ser732 in diabetic
HIP rats was not an artifact of decreased b-cell mass, we
FIG. 5. Downstream of CDK5, Fak is directly involved in b-cell survival. A: INS 832/13 cells were transfected with scramble (Sc) or Fak
siRNAs (50 nmol/L, 48 h). Protein levels of Fak, P-Fak
Ser732, P-Fak
Tyr397, and cleaved caspase-3 were analyzed by Western blot. GAPDH was used as
loading control. The graph represents the quantiﬁcation of the Western blot (n =3 ) .B–D: pBabe and Fak-INS 832/13 cells were treated with or
without roscovitine (40 µm, 24 h). B: Fak and Akt protein levels and Fak
Ser732, Akt
Ser473 phosphorylation levels were analyzed by Western blot.
GAPDH was used as loading control. The graphs represent the quantiﬁcation of the Western blots (n =3 ) .C: Apoptosis was assessed by immu-
noﬂuorescence staining using an antibody directed against the cleaved form of caspase-3 (red). Nuclei were stained with DAPI (blue). The graph
represents the quantiﬁcation of the number of cells positive for cleaved caspase-3, expressed in % (n =3 ) .D: Cell death was assessed by PI
staining (red). The graph represents the quantiﬁcation of the relative number of PI positive cells compared with control cells (n = 3). *P < 0.05,
**P < 0.01, ***P < 0.001, signiﬁcant differences. RU, relative units. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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1192 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgFIG. 6. CDK5 overexpression protects b-cells against apoptosis induced by the inhibition of b-1 integrin signaling pathway. A and B: INS 832/13
cells were left untreated or incubated with 20 µg/ml of IgM antibody as control or b-1 integrin-blocking antibody for 24 h. A: Protein levels of Fak,
CDK5, p35, Akt, and phosphorylation levels of Fak
Ser732, Akt
Ser473 were analyzed by Western blot. GAPDH was used as loading control. The graphs
represent the quantiﬁcation of the Western blots (n =3 ) .B: Apoptosis was assessed by immunoﬂuorescence staining using an antibody directed
against the cleaved form of caspase-3 (red). Nuclei were stained with DAPI (blue). The graph represents the quantiﬁcation of the number of cells
positive for cleaved caspase-3, expressed in % (n =3 ) .C: INS 832/13 cells were left untreated or transfected for 24 h with GFP (0.4 mg), CDK5-GFP
(0.4 mg), CDK5-GFP (0.2 mg) + p35-myc (0.2 mg). Cells were then incubated with IgM antibody as control or b-1 integrin-blocking antibody for
additional 24 h. Cell death was assessed by PI staining (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, signiﬁcant differences. #P < 0.05, signiﬁcant
differences vs. IgM-treated cells. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Ser732 is decreased in b-cells in rats with diabetes. A: The phosphorylation state of Fak
Ser732 and CDK5 protein level
were assessed by Western blot using lysates obtained from 4- to 6-month-old WT (n = 6) and prediabetic HIP rats (n =6 )( left panel) and 9- to
11-month-old WT (n = 4) and HIP rats with diabetes (n =4 )( right panel). GAPDH and insulin were used as control. The graphs represent the
quantiﬁcation of the Western blot. **P < 0.01, signiﬁcant differences vs. WT. B: The presence of Fak
Ser732 phosphorylation in b-cells was assessed
by immunoﬂuorescence (P-Fak
Ser732, red; Insulin, green; Nuclei, blue) in pancreatic tissue obtained from 4- to 6-month-old WT (n = 2) and pre-
diabetic HIP rats (n =2 )( left panels) and 9- to 11-month-old WT (n = 3) and HIP rats with diabetes (n =3 )( right panels). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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Ser732
in rat pancreata (Fig. 7B). The results were in agreement
with the Western blot data. There was no difference in
P-Fak
Ser732 staining between prediabetic HIP and WT
rats. However, P-Fak
Ser732 immunostaining was decreased
in the cytoplasm of b-cells from diabetic HIP rats in com-
parison with age-matched WT rats (Fig. 7B).
Moreover, P-Fak
Ser732 staining in b-cells from diabetic
HIP rats revealed almost exclusive nuclear localization.
Prior studies have reported a nuclear localization of Fak
under conditions of cellular stress (26). Therefore, the high
level of b-cell apoptosis present in diabetic HIP rats might
explain the presence of nuclear P-Fak
Ser732.
Of note, a close parallel was observed between P-Fak
Ser732
and P-Fak
Tyr397 levels in rat b-cells. Indeed, P-Fak
Tyr397 levels
were no different to WT controls in prediabetic HIP rat islets
but were decreased in HIP rats with diabetes (Supplemen-
tary Fig. 6A and B).
In contrast to the decreased P-Fak in b-cells in HIP rats
with diabetes, suggesting a deﬁcit in CDK5 activity under
these conditions, P-ERK1/2 expression was increased in
HIP rat islets with diabetes (Supplementary Fig. 7). This
ﬁnding implies that CDK5 does not directly regulate the
mitogen-activated protein kinase pathway in b-cells.
Phosphorylation of Fak
Ser732 is decreased in b-cells in
humans with type 2 diabetes. To determine whether the
decrease in P-Fak
Ser732 observed in HIP rats is relevant to
humans with type 2 diabetes, pancreata obtained from 4
nondiabetic control subjects and 6 individuals with type 2
diabetes were stained for P-Fak
Ser732. Analysis of these
pancreata revealed a diminished staining in b-cells of
individuals with type 2 diabetes (Fig. 8). Quantiﬁcation of
the number of b-cells with cytoplasmic staining showed
a 45% decrease in P-Fak
Ser732 in type 2 diabetes (P , 0.05).
Consistent with the data obtained in the b-cells in the HIP
rat, these observations imply that P-Fak
Ser732 is decreased
in b-cells in humans with type 2 diabetes, implying either
insufﬁcient CDK5 kinase activity or an impaired response
to the CDK5 kinase.
DISCUSSION
In this study, we tested the hypothesis that CDK5 hyper-
activation contributes to h-IAPP–induced apoptosis. The
reasons for testing this postulate were the close similarity
between cellular pathology in islets in type 2 diabetes and
neurons in Alzheimer’s disease, together with the pro-
posed role of CDK5 hyperactivation in AbP-induced neu-
ronal cell apoptosis (15,18,27). The data presented here
permit us to comprehensively reject that hypothesis with
regard to h-IAPP toxicity in b-cells in type 2 diabetes.
Unexpectedly, these studies did uncover a role for CDK5
activity in sustaining b-cell survival by regulating Fak
phosphorylation and PI3K/Akt survival pathway.
ER stress and altered calcium homeostasis have been
reported in both h-IAPP– and AbP-mediated toxicity
(21,28). Neuronal overexpression of AbP induces calpain-
mediated cleavage of p35 and the appearance of the p25
truncated fragment that leads to CDK5 hyperactivation
and relocalization (29,30). The fact that h-IAPP did not
induce p35 cleavage implies that the subcellular com-
partments disrupted by these misfolded proteins likely
differ. Thus, while both IAPP and AbP oligomers have
been shown to induce membrane disruption, AbPi sl o c a l -
ized to the greatest extent at the cell membrane, whereas
IAPP is located predominantly within the secretory pathway
where the oligomers of IAPP have been shown to form (14).
As such, it is perhaps not surprising that the former might
have a greater effect to displace CDK5 from the plasma
membrane than the latter. In b-cells, ER stress induced by
thapsigargin led to a modest cleavage of p35. However,
even under those conditions, CDK5 activity was still pro-
tective. Also, because p35 levels remained much higher
than p25 levels, it seems reasonable to postulate that CDK5/
p35 complexes may still prevail over CDK5/p25 complexes.
Furthermore, the decreased P-Fak
Ser732 levels observed
here following thapsigargin treatment do not support
hyperactivation of CDK5. Thus neither thapsigargin nor
IAPP-induced ER stress sufﬁcient to induce apoptosis in
b-cells promoted CDK5 hyperactivation. By implication,
FIG. 8. Phosphorylation of Fak
Ser732 is decreased in b-cells in humans with type 2 diabetes. A: The presence of Fak
Ser732 phosphorylation in b-cell
was assessed by immunoﬂuorescence (P-Fak
Ser732, red; Insulin, green; Nuclei, blue) in surgical pancreatic tissue obtained from nondiabetic control
subjects (n = 4) and subjects with type 2 diabetes (n =6 ) .B: The graph represents the quantiﬁcation of b-cells positive for P-Fak
Ser732, expressed
in %. *P < 0.05, signiﬁcant differences. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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an important mediator of ER stress-induced apoptosis in
neurons, this does not appear to be the case in pancreatic
b-cells.
Only a few studies have focused so far on the role of
CDK5 in pancreatic b-cells. In INS-1 cells, elevation of
extracellular glucose concentrations induces p35 expres-
sion and activates the CDK5/p35 complex, which enhances
insulin promoter activity (7). Inhibition of CDK5 has been
reported to protect INS-1 cells from glucotoxicity (31).
Different groups have also studied the role of CDK5 in
glucose-stimulated insulin secretion and have reached
contradictory conclusions. Studies reported that insulin
secretion is enhanced by inhibition of CDK5 (11–13)
whereas another group reported that CDK5 promotes in-
sulin exocytosis (8,10). The latter study reported in addi-
tion that regulation of insulin exocytosis is speciﬁcally
mediated by the complex CDK5/p39 and does not involve
p35 (8).
Distinct roles in the regulation of CDK5 activity have
been attributed to p35 and p39 in the brain using knockout
models (32). Loss of p35 seems to be more detrimental to
CDK5 function and although p39 expression is upregulated
in the brain of p35
2/2 mice, it is only able to compensate to
a limited extent for the loss of p35. To the contrary, the
loss of p39 appears to be fully compensated by p35 (32).
Similarly, in our study, the increase in apoptosis following
p35 knockdown was comparable to that seen with CDK5
knockdown, implying that p39 does not compensate for
the loss of p35. This suggests that p35 and p39 may also
play different roles in b-cells; p35 may be responsible for
a prosurvival activity of CDK5, whereas p39 may be more
important in b-cell function (8).
A prosurvival/proapoptotic duality of CDK5 has been
noted in neurons. Mice that are deﬁcient in CDK5 die just
before or after birth because of an impaired neuro-
development and neuron degeneration, suggesting a role
of CDK5 in neuron survival (33). In contrast to CDK5/p25
complex associated with apoptosis, CDK5 association with
p35 seems to be required for neuronal survival through the
activation of ERK1/2 and PI3K/Akt pathways (34,35). In
our study, the loss of CDK5 in both INS 832/13 cells and
primary b-cells resulted in an attenuation of PI3K/Akt
survival pathway and increased b-cell apoptosis. We pro-
pose here that the mechanism responsible for this effect
involves a decrease in P-Fak
Ser732 as a consequence of CDK5
inhibition. Fak
Ser732 has been identiﬁed as a target of CDK5
in neurons and implicated in microtubule organization and
neuronal migration (22). Fak is generally activated by
integrins and growth factors and regulates various signal-
ing pathways related to cytoskeletal organization, cell pro-
liferation, and cell survival (23,25). Integrins and growth
factors are widely recognized as important regulators of
b-cell function and survival (36–43). However, the role of
P-Fak in b-cells remains unknown. In other cell types, Fak
interacts with IRSs and PI3K, thereby stimulating growth
and survival pathways (44–46). IRS2 and Akt are both
major regulators of b-cell survival (24). Our ﬁndings sug-
gest that the regulation of Fak activity and subsequently
Akt survival pathway may represent a mechanism by
which CDK5 promotes b-cell survival.
The deﬁcit in P-Fak
Ser732 in HIP rats became apparent
with development of diabetes, implying that the deﬁcit in
P-Fak
Ser732 is either secondary to and/or may contribute to
the decompensation of b-cell function and survival that
occurs after the onset of hyperglycemia. Because ER
stress and increased b-cell apoptosis are already present
in the HIP rat preceding diabetes onset, the deﬁcit in
P-Fak
Ser732 is presumably not simply a consequence of the
apoptosis. The integrity of islet morphology, maintained by
cell-cell and cell-extracellular matrix interactions, has
been reported to be essential for sustaining b-cell survival
and function (47–49). Besides increased apoptosis and
decreased b-cell function, type 2 diabetes is also charac-
terized by a disruption of islet architecture (27). This dis-
ruption occurs at least in part because of the presence of
extensive amyloid deposits and membrane disrupting
properties of h-IAPP oligomers (14,27,50). Disruption of islet
morphology resulting in the disengagement of cell adhesion
molecules, integrin receptors, and focal adhesions could
contribute to the decrease in the Fak signaling pathway
found in rats and humans with type 2 diabetes. On the other
hand, given the role of the Fak pathway to foster cell-to-cell
communication, the newly reported prosurvival function
of the CDK5 complex to promote cell survival through
activation of Fak may palliate the actions of extracellular
amyloid and cell membrane IAPP oligomers to disrupt
cell-to-cell communication int h ei s l e ti nt y p e2d i a b e t e s .
In conclusion, there is an as yet unexplained linkage
between CDKAL1 and type 2 diabetes in humans. Although
further studies will be necessary to determine the exact
nature of the CDKAL1 variant and its inﬂuence on CDK5,
we present data here that reveal a previously unrecognized
role of the CDK5 complex in b-cell survival, mediated
through activation of the Fak and Akt pathways. These
data thus provide a novel mechanism by which variance in
CDKAL1 might inﬂuence the risk for type 2 diabetes.
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